Home
HelpTest Code FINA NAbFeron (IFNB-1) Neutralizing Antibody Test
Reporting Name
NAbFeron (IFN-B) AntibodyUseful For
Detection of antibodies to interferon-B-1
Performing Laboratory
Athena DiagnosticsSpecimen Type
SerumSpecimen Required
Specimen Type: Serum
Container/Tube: Red or SST
Specimen Volume: 2 mL
Collection Instructions: Draw blood in a plain red-top tube(s), serum gel tube is acceptable. Spin down and send 2 mL of serum refrigerate in a plastic vial.
Note: Sample needs to be collected either before treatment with interferon or more than 24 hours following the most recent dose. Patient should not be on steroid therapy for at least two weeks prior to testing.
Specimen Minimum Volume
0.5 mL
Specimen Stability Information
| Specimen Type | Temperature | Time |
|---|---|---|
| Serum | Refrigerated (preferred) | 28 days |
| Frozen | 180 days | |
| Ambient | 72 hours |
Reference Values
Final report has been sent to the referring laboratory.
Day(s) Performed
Monday through Friday
Test Classification
This test was developed and its analytical performance characteristics have been determined by Athena Diagnostics. It has not been cleared or approved by U.S. Food and Drug Administration. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes. .CPT Code Information
86382
LOINC Code Information
| Test ID | Test Order Name | Order LOINC Value |
|---|---|---|
| FINA | NAbFeron (IFN-B) Antibody | Not Provided |
| Result ID | Test Result Name | Result LOINC Value |
|---|---|---|
| Z0083 | NAbFeron (IFN-B) Antibody | Not Provided |
Clinical Reference
- Goodin, DS, et al. (2007) Neurology 68:977-984 (PMID: 17389300)
- Polman, CH, et al.(2010) Lancet Neurol 9:740-50 (PMID: 20610349)
- Creeke, Pl, et al. (2013) Ther Adv Neurol Disord 6:3-17 (PMID: 23277789)
Report Available
14 to 25 daysReject Due To
| Hemolysis | NA |
| Lipemia | NA |
| Icterus | NA |
| Other | NA |
NY State Approved
YesMethod Name
Viral cytopathic effect assay
Secondary ID
91447Cautions
The present of neutralizing antibodies to interferon beta, especially in persistently high titers, may be associated with reduction in the clinical effectiveness of interferon beta therapy (1). Although the measurement of Nabs can add to the clinical and imaging information used to assess the efficacy of interferon beta therapy, these results should be interpreted in the context of clinical presentation and medical history (2, 3).
Although rare, false positive or false negative results may occur. All results should be interpreted in the context of clinical findings, relevant history, and other laboratory data.